Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Thursday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is projected to announce its Q1 2026 results after the market closes on Thursday, February 5th. Analysts expect Arrowhead Pharmaceuticals to post earnings of $0.82 per share and revenue of $225.6580 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, February 5, 2026 at 4:30 PM ET.

Arrowhead Pharmaceuticals Trading Down 2.0%

Shares of ARWR stock opened at $65.58 on Thursday. The company has a market capitalization of $8.91 billion, a PE ratio of -819.65 and a beta of 1.21. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $76.76. The business’s fifty day moving average is $64.01 and its 200 day moving average is $41.11. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. The Goldman Sachs Group increased their target price on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, January 7th. B. Riley raised their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. HC Wainwright boosted their price target on Arrowhead Pharmaceuticals from $85.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, January 21st. Morgan Stanley upped their price target on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 7th. Finally, Royal Bank Of Canada increased their price objective on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $81.67.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 40,164 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $2,534,750.04. Following the completion of the transaction, the insider directly owned 171,958 shares of the company’s stock, valued at $10,852,269.38. The trade was a 18.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Patrick O’brien sold 49,493 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $3,123,503.23. Following the sale, the chief operating officer owned 474,908 shares of the company’s stock, valued at approximately $29,971,443.88. The trade was a 9.44% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 510,836 shares of company stock valued at $33,603,060. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ARWR. Arrowstreet Capital Limited Partnership boosted its position in Arrowhead Pharmaceuticals by 3,142.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock worth $71,797,000 after acquiring an additional 2,017,489 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 34.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock valued at $22,189,000 after acquiring an additional 447,456 shares during the last quarter. Woodline Partners LP raised its holdings in Arrowhead Pharmaceuticals by 34.0% in the 3rd quarter. Woodline Partners LP now owns 1,000,158 shares of the biotechnology company’s stock worth $34,495,000 after acquiring an additional 254,002 shares during the period. Deerfield Management Company L.P. acquired a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth about $34,249,000. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Arrowhead Pharmaceuticals during the third quarter worth approximately $27,349,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.